More recently, treatment with antibodies to programmed cell death protein 1 (PD-1), one of the immunological approaches, has been shown to be successful only in treating microsatellite instability-high tumors, which leaves 85% of CRC patients unable to benefit from immunotherapy (5–8). The gene discussed is PDCD1; the disease is colorectal carcinoma.